A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...
EyePoint Pharmaceuticals' DURAVYU trials for wet AMD receive positive DSMC review, highlighting safety and potential for ...
The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...
No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety ...
In this video, David A. Eichenbaum, MD, FASRS, discusses late-stage wet age-related macular degeneration assets presented at the American Academy of Ophthalmology meeting.Eichenbaum noted that ...
AMD's next CPU launch is going to be the Gorgon Point family. Don't wet yourself in excitement; they're primarily refreshed ...
Optometrist Amy Green discussed the importance of OCT in identifying AMD cases during the AOP’s Locum Clinical Skills ...
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory ...
Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...
The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...
EyePoint Pharmaceuticals ( ($EYPT) ) has provided an announcement. On November 19, 2025, EyePoint Pharmaceuticals announced a positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback